Source: https://www.global-regulation.com/law/australia/229113/national-health-%2528efficient-funding-of-chemotherapy%2529-special-arrangement-amendment-instrument-2012-%2528no.-4%2529-%2528no.-pb-36-of-2012%2529.html
Timestamp: 2018-12-16 08:08:05
Document Index: 151320967

Matched Legal Cases: ['art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1']

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 4) (No. PB 36 of 2012) (Australia)
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 4) (No. PB 36 of 2012)
Link to law: https://www.comlaw.gov.au/Details/F2012L01118
PB 36 of 2012
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 4)
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 25 May 2012
(1) This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 4).
(2) This Instrument may also be cited as PB 36 of 2012.
This Instrument commences on 1 June 2012.
3 Amendments to PB 79 of 2011
Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
[1] Schedule 1 Part 1, after entry for Gemcitabine in the form Powder for I.V. infusion 1 g (as hydrochloride) with manner of administration Injection and brand DBL Gemcitabine for Injection
Gemaccord
[2] Schedule 1 Part 1, after entry for Gemcitabine in the form Powder for I.V. infusion 200 mg (as hydrochloride) with manner of administration Injection and brand DBL Gemcitabine for Injection
[3] Schedule 1 Part 1, after entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL with manner of administration Injection and brand Hospira Pty Limited
Irinoccord
C3184
[4] Schedule 1 Part 1, after entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL with manner of administration Injection and brand Hospira Pty Limited
[5] Schedule 1 Part 1, after entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 100 mg in 20 mL with manner of administration Injection and brand Eloxatin
Oxaliccord
C3900 C3901 C3930 C3939
[6] Schedule 1 Part 1, after entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 50 mg in 10 mL with manner of administration Injection and brand Eloxatin